Weight Loss and Metabolic Effects

Phase 2 dose-response data and metabolic improvements beyond body weight

Beyond a GLP-1 Agonist

Survodutide produced up to 19% body weight loss at 46 weeks in Phase 2, with simultaneous improvements in glycemic control, liver fat, and cardiometabolic markers. This unit breaks down the dose-response curve, the diabetes trial data, and the metabolic effects that extend beyond the scale.

Interactive Clinical Results

Explore dose-dependent outcomes across the Phase 2 obesity and diabetes trials.

clinical results dashboard

Knowledge Check

Test your understanding of survodutide's clinical weight loss and metabolic data.

Practice

Apply the clinical data concepts before moving to the trial landscape.